Mercedes Cano, Antonio Ayala, Francesco Marotta and Sandro Arguelles* Pages 4351 - 4368 ( 18 )
Protein phosphorylation, mediated by protein kinases, has important physiological and pathological implications in our lives. Targeting kinase is one of the most interesting of the emerging topics in the pharmaceutical industry, especially since there is a focus on cancer therapy. Given that kinases may be involved in the aging process the focus will be on using the kinase inhibitor for anti-aging intervention to enhance healthspan and increase longevity. In this review, we will summarize: (i) the impact of the phosphoproteomic approach to elucidate molecular mechanisms of diseases; (ii) importance of the drug discovery approach for targeting kinases; (iii) the dysregulation of Janus kinase (JAK) / signal-transducing adapter molecules (STAT) and p70 ribosomal protein S6 kinase (S6Ks) pathway in aging and the age-related process; (iv) the epidemiological studies available in order to see whether a correlation between JAK/STAT and S6Ks mRNA expression levels exist in cancer and in patient outcome; (v) finally, we will show selected inhibitors of these kinases approved by the US Food and Drug Administration (FDA).
Protein kinases, anti-aging, kinase inhibitor, janus kinase (JAK), phosphoproteomic, S6K, healthspan, longevity.
Department of Physiology, Faculty of Pharmacy, University of Seville, Seville, Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Seville, Seville, ReGenera Research Group for Aging Intervention and San Babila Clinic, Milano, Department of Physiology, Faculty of Pharmacy, University of Seville, 41012 Seville